NCT05343325View on ClinicalTrials.gov

The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 9, 2022

Primary Completion Date

March 31, 2024

Study Completion Date

March 31, 2027

Conditions
Head and Neck Squamous Cell CarcinomaNeoadjuvant Treatment
Interventions
DRUG

Tislelizumab

Tislelizumab: 200 mg D1, Q3W for two cycles. Albumin-bound paclitaxel: 100mg/m2, D1, D8, D15, Q3W for two cycles. Cisplatin: 25mg/m2, D1, D8, D15, Q3W for two cycles.

RADIATION

Low-dose radiotherapy

Low-dose radiotherapy: 1GY/1F, D1, D2, D8, D15, Q3W for two cycles. The total radiation dose will be GTV 8Gy/8F, GTVnd 8 Gy/8F.

Trial Locations (2)

519000

RECRUITING

Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai

523059

RECRUITING

Zhigang Liu, Dongguan

All Listed Sponsors
collaborator

Dongguan People's Hospital

OTHER_GOV

lead

Fifth Affiliated Hospital, Sun Yat-Sen University

OTHER